Human-first Biodynamic Discovery Platform™ employs cutting-edge chemistry, neuroscience and machine learning to develop plant- and fungi-inspired therapeutics to address global crises
The company’s scientific founders include leading experts in neuroscience, chemistry, and psychiatry
Funding led by Santé Ventures, Route 66 Ventures and CU Healthcare Innovation Fund
boston, November 8, 2022 /PRNewswire/ — Sensorium Therapeutics (Sensorium), a biotechnology company that leverages medicinal chemistry, neuroscience and machine learning to develop naturally-inspired psychotropic drugs for mental health, today announced that $30 million Series A funding to advance the initial asset, SENS-01, and the Biodynamic Discovery Platform™ (BDP), a drug discovery engine that rapidly identifies, synthesizes and enhances targeted molecules as novel therapeutics. The round was led by Santé Ventures, an investment firm focused on healthcare and life sciences. billion dollars Route 66 Ventures, CU Healthcare Innovation Fund, WPSS.bio, Palo Santo, Iter Investments, Ocama Partners and re.Mind Capital participate and invest in the capital under management.
“To expand the world of safe and effective treatments by harnessing our knowledge of what has worked in human populations for centuries to address this devastating mental health crisis. is urgently needed. Dick Simon, CEO and co-founder of Sensorium. “The complexity of the challenge requires clinical, scientific, and technical expertise. Sensorium’s multidisciplinary team represents a wealth of industry and academic experience with a passion for impact and a proven track record.” doing.”
Sensorium, with co-founders from leading institutions with expertise in psychiatry, chemistry and neuroscience, harnesses the vast chemical space of psychoactive molecules to develop new medicines to address global crises By doing so, we are trying to overcome historical challenges in central nervous system drug development. BDP feeds proprietary machine learning algorithms with data output and high-throughput characterization from natural product libraries, starting with extensive long-term human use-based efficacy and safety evidence. By prioritizing mechanisms with well-established efficacy in the human brain, the platform will enable Sensorium to deliver modern medicines faster, improve efficacy and tolerability, reduce side effects and reduce addiction. allows you to reduce the chance of
The company’s first asset, SENS-01, shows the potential for rapid therapeutic effect to treat anxiety. Sensorium is developing his SENS-01 as a fast-acting and well-tolerated treatment for patients with anxiety and depression, and in 2023 he will begin IND-enabling research and will continue to work towards 2024. It is expected to enter the clinic by the beginning of the year.
“Sensorium’s innovative technology and experienced research team have the potential to revolutionize neuropsychiatric therapy by developing multiple new classes of novel treatments. Kevin Laland, Founding Managing Director of Santé Ventures. “We are delighted to support the Sensorium team in their mission to build these new therapeutic pathways and bring new medicines to many patients suffering from urgent mental health needs.”
Sensorium’s scientific co-founder added:
- “By better understanding how new psychoactive molecules affect the brain, we can provide innovative medicines to patients for whom existing therapies are inadequate and who are desperately waiting for innovation.” Unlock critical insights from Doctor jerry rosenbaumco-founder of Sensorium, Emeritus Psychiatrist and Emeritus Director, Center for Anxiety and Traumatic Stress Disorders, Massachusetts General Hospital (MGH). Director of the Neuroscience Center for Psychedelics.Professor of Psychiatry Stanley Cobb Harvard Medical School.
- “Our predictive knowledge network of psychoactive molecules serves as a starting point for identifying structure-activity relationships and developing new pharmaceuticals with optimized therapeutic benefits. We deliver and we know we can do it better.” Jacob HookerPh.D., co-founder of Sensorium, Scientific Director of MGH’s Lurie Center for Autism, Phyllis and Jerome Lyle Rappaport MGH Research Scholar, and Professor of Radiology Harvard Medical School.
- “Humans have been consuming psychoactive molecules for centuries, but understanding how they work has remained a challenge. It connects with a platform that explores drug function on neuronal plasticity and other indicators to generate potential drug candidates.” Stephen HaggertyPh.D., co-founder of Sensorium, Associate Professor of Neurology Harvard Medical SchoolAssociate Neuroscientist at MGH and Director of the MGH Institute of Chemistry and Neurobiology.
The funding will also support the advancement of Sensorium’s platform and early programs, as well as ensure the growth of the company’s multidisciplinary team of professionals who are passionate about improving mental health.
About Sensorium Therapeutics
Founded by world-class researchers, clinicians and drug developers at Massachusetts General Hospital, Harvard Medical School, Sensorium Therapeutics, is a biotechnology company that uses cutting-edge chemistry, neuroscience and machine learning to develop naturally-inspired psychotropic drugs for mental health. Sensorium’s breakthrough Biodynamic Discovery Platform™ rapidly identifies, replicates, adapts, enhances, and innovates target molecules, beginning with evidence of efficacy and safety based on long-term and extensive human use of plants and fungi. enhance their utility as modern medicines that can provide substantial benefits. patients around the world. See sensorium.bio for more information.
Source: Sensorium Therapeutics
